Transgene
Unlocking the Full Potential of the Immune System Against Cancer
Transgene is a biotechnology company that designs and develops cutting-edge immunotherapeutics to fight cancer.
Its approaches aim to specifically stimulate and train the immune system to recognize and destroy cancer cells.
With myvac®, its individualized therapeutic vaccine platform, Transgene is reshaping the future of early-stage cancer treatment.
The myvac® platform: 1 patient – 1 cancer – 1 vaccine
- Individualized treatment tailor-made for each patient using artificial intelligence and bioinformatics.
- TG4050, the first individualized therapeutic vaccine candidate from the myvac® platform, is undergoing a Phase 1/2 trial in adjuvant treatment of head and neck cancers to prevent recurrence after surgery.
“Our next-generation immunotherapies mark a turning point for patients: by harnessing the body’s
natural defense mechanisms, we empower them with the tools to fight the disease with precision and effectiveness. This innovative approach paves the way for individualized treatments that have enduring effects and bring hope for conditions that have long been difficult to treat.”
160
employees based in Strasbourg
72%
of staff dedicated to research & innovation